237 related articles for article (PubMed ID: 20006625)
21. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
Ko BS; Jan YJ; Chang TC; Liang SM; Chen SC; Liu TA; Wu YM; Wang J; Liou JY
Anticancer Agents Med Chem; 2013 May; 13(4):555-62. PubMed ID: 22934705
[TBL] [Abstract][Full Text] [Related]
22. Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene expression in human leukemia U937 cells.
Moon DO; Kim MO; Lee JD; Kim GY
Cancer Lett; 2008 Jun; 264(2):192-200. PubMed ID: 18314260
[TBL] [Abstract][Full Text] [Related]
23. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
25. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
26. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
[TBL] [Abstract][Full Text] [Related]
27. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibition: a new approach for the treatment of malignancies.
Spano JP; Bay JO; Blay JY; Rixe O
Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
30. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
31. Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.
Tse AK; Wan CK; Shen XL; Yang M; Fong WF
Biochem Pharmacol; 2005 Nov; 70(10):1443-57. PubMed ID: 16181613
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
[TBL] [Abstract][Full Text] [Related]
33. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
34. The proteasome inhibitor bortezomib augments anti-proliferative effects of mistletoe lectin-I and the PPAR-gamma agonist rosiglitazone in human melanoma cells.
Freudlsperger C; Thies A; Pfüller U; Schumacher U
Anticancer Res; 2007; 27(1A):207-13. PubMed ID: 17352234
[TBL] [Abstract][Full Text] [Related]
35. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
Chen FT; Liu YC; Yang CM; Yang CH
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3682-94. PubMed ID: 22538426
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
38. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
[TBL] [Abstract][Full Text] [Related]
39. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
40. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
